Bioqual Presents Unaudited Financial Results for Second Quarter of Fiscal Year 2024

Rhea-AI Summary

BIOQUAL, Inc. (BIOQ) reports a slight decrease in revenue for the six months ended November 30, 2023, compared to the same period in 2022. The company also experienced a decline in income before income tax and net income. Basic and diluted earnings per share of common stock also decreased. The unaudited second quarter results can be found on the company's website. Forward-looking statements are subject to risks and uncertainties.

Positive

• None.

Negative

• Slight decrease in revenue for the six months ended November 30, 2023, compared to 2022
• Decline in income before income tax and net income
• Decrease in basic and diluted earnings per share of common stock

ROCKVILLE, Md.--(BUSINESS WIRE)-- BIOQUAL, Inc. (OTC Pink: BIOQ) www.bioqual.com:

	Six Months Ended						Three Months Ended
	November 30,						November 30,
		2023			2022			2023			2022
Revenue	$	31,448,326		$	32,487,702		$	15,869,404		$	16,677,128
Income Before Income Tax	$	1,909,744		$	3,784,494		$	668,561		$	1,828,834
Net Income	$	1,384,144		$	2,677,394		$	484,661		$	1,293,834
Basic Earnings per Share of Common Stock	$	1.55		$	2.99		$	0.54		$	1.45
Diluted Earnings per Share of Common Stock	$	1.55		$	2.99		$	0.54		$	1.45
Weighted Average
Number of Shares Outstanding For Basic Earnings Per Share		894,416			894,416			894,416			894,416
Weighted Average
Number of Shares Outstanding For Diluted Earnings Per Share		894,398			894,417			894,390			894,428

For more detail related to the fiscal year 2024 unaudited second quarter results, please visit our web site at www.bioqual.com.

Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. The forward-looking statements are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to obtain sufficient numbers of animal models; the availability of adequate numbers of employees; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240123909856/en/

Mark G. Lewis, Ph.D., CEO (240-404-7654)

Source: Bioqual

FAQ

What is BIOQUAL, Inc.'s ticker symbol?

BIOQUAL, Inc.'s ticker symbol is BIOQ.

What was the revenue for BIOQUAL, Inc. for the six months ended November 30, 2023?

The revenue for BIOQUAL, Inc. for the six months ended November 30, 2023, was $31,448,326.

Where can I find the unaudited second quarter results for BIOQUAL, Inc.?

The unaudited second quarter results for BIOQUAL, Inc. can be found on their website at www.bioqual.com.

What are the basic and diluted earnings per share of common stock for BIOQUAL, Inc. for the three months ended November 30, 2023?

The basic and diluted earnings per share of common stock for BIOQUAL, Inc. for the three months ended November 30, 2023, were $0.54.

Are there any risks associated with BIOQUAL, Inc.'s forward-looking statements?

Yes, statements that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties.

What is the income before income tax for BIOQUAL, Inc. for the six months ended November 30, 2022?

The income before income tax for BIOQUAL, Inc. for the six months ended November 30, 2022, was $3,784,494.